Articles

PP23 A simple frailty score to identify patients with malignant hemopathies who don’t benefit from standard dose chemotherapy

BJH - 2018, issue Abstract Book BHS, february 2018

S. Dubruille PhD, C. Kenis , Y. Libert PhD, M. Delforge MD, PhD, L. Dal Lago , M. Roos , C. Borghgraef , A. Salaroli MD, M. Maerevoet MD, D. Razavi MD, PhD, H. Wildiers , D. Bron MD, PhD

Read more

O.1 A new frailty scoring in ‘clinically fit’ older patients with malignant hemopathies admitted to receive chemotherapy

BJH - volume 8, issue Abstract Book BHS, february 2017

S. Dubruille PhD, C. Kenis , Y. Libert PhD, M. Delforge MD, PhD, J. Alexis Ruiz , M. Roos , A. Collard , N. Meuleman MD, PhD, M. Maerevoet MD, D. Razavi MD, PhD, H. Wildiers , D. Bron MD, PhD

Read more

P1.12 Identification of clinical and biological parameters predictive of chemotherapy completion and two-year overall survival in clinically fit older patients with haematological malignancies

BJH - volume 7, issue Abstract Book BHS, january 2016

S. Dubruille PhD, Y. Libert PhD, M. Roos , S. Vandenbossche , A. Collard , N. Meuleman MD, PhD, M. Maerevoet MD, A. Etienne , C. Reynaert , D. Razavi MD, PhD, D. Bron MD, PhD

Read more

P2.17 The respective value of the G8 screening and the Comprehensive Geriatric Assessment (CGA) for the identification of vulnerable older patients with hematological malignancies susceptible to benefit from chemotherapy

BJH - volume 5, issue Abstract Book BHS, january 2014

S. Dubruille PhD, Y. Libert PhD, M. Roos , S. Vandenbossche , N. Meuleman MD, PhD, M. Maerevoet MD, D. Razavi MD, PhD, D. Bron MD, PhD

Read more

P.36 Management of fit older AML: major prognostic value of cytogenetic markers is confirmed whatever the age

BJH - 2013, issue BHS Abstractbook, january 2013

J. Nguyen , B. Bailly MD, P. Sidon , J. Hotton , M. Roos , M. Maerevoet MD, P. Lewalle MD, PhD, N. Meuleman MD, PhD, M. Paesmans , D. Bron MD, PhD

Read more